Updated on 2 September 2014
As an irony of sorts, one of the biggest scandals witnessed by the pharmaceutical industry took place in the country with the world's most stringent laws. Even as big and small firms continue to make inroads into China, language barriers and regulatory understanding, notwithstanding, many with already a set base and millions in revenue from the region, are concerned.
What started as a nation-wide check into pricing of pharmaceutical products in February last year led to revelations that have shook decade long existences of leading companies in the country.
In May this year, the Chinese police finally closed the 10-month-long investigation into British drug maker GlaxoSmithKline, charging the former China head of the drug maker, Mr Mark Reilly with bribery.
The probe led the cops into establishing how billions of yuan were paid in bribes to doctors and hospitals. The police in the Hunan province said that Mr Mark Reilly, along with two Chinese executives, Mr Zhang Guo-wei and Mr Zhao Hongyan, were suspected of bribing officials in the industry and commerce departments of Beijing and Shanghai.